Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen mRNA Tumor Vaccine in Advanced Esophageal and NSCLC
NCT03908671Phase 1Recruiting
- Sponsor
- Stemirna Therapeutics
- Start
- Oct 2019
- Primary completion
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Stemirna personalized mRNA tumor vaccine in esophageal cancer and non-small cell lung cancer (NSCLC), sponsored by Stemirna Therapeutics. Primary endpoint: Number of participants with treatment-related adverse events at 24 weeks. Started Oct 2019; status: recruiting.
02
Drugs
Stemirna personalized mRNA tumor vaccine
03
Conditions
esophageal cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03908671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03908671.